Serum 25-hydroxyvitamin D, mortality, and incident cardiovascular disease, respiratory disease, cancers, and fractures: a 13-y prospective population study1–4

Kay-Tee Khaw, Robert Luben, and Nicholas Wareham

ABSTRACT

Background: Vitamin D is associated with many health conditions, but optimal blood concentrations are still uncertain.

Objectives: We examined the prospective relation between serum 25-hydroxyvitamin D [25(OH)D] concentrations [which comprised 25(OH)D$_3$ and 25(OH)D$_2$] and subsequent mortality by the cause and incident diseases in a prospective population study.

Design: Serum vitamin D concentrations were measured in 14,641 men and women aged 42–82 y in 1997–2000 who were living in Norfolk, United Kingdom, and were followed up to 2012. Participants were categorized into 5 groups according to baseline serum concentrations of total 25(OH)D <30, 30 to <50, 50 to <70, 70 to <90, and ≥90 nmol/L.

Results: The mean serum total 25(OH)D was 56.6 nmol/L, which consisted predominantly of 25(OH)D$_3$ (mean: 56.2 nmol/L; 99% of total). The age-, sex-, and month-adjusted HRs (95% CIs) for all-cause mortality (2776 deaths) for men and women by increasing vitamin D category were 1, 0.84 (0.74, 0.94), 0.72 (0.63, 0.81), 0.71 (0.62, 0.82), and 0.66 (0.55, 0.79) (P-trend < 0.0001). When analyzed as a continuous variable and with additional adjustment for body mass index, smoking, social class, education, physical activity, alcohol intake, plasma vitamin C, history of cardiovascular disease, diabetes, or cancer, HRs for a 20-nmol/L increase in 25(OH)D were 0.92 (0.88, 0.96) (P < 0.001) for total mortality, 0.96 (0.93, 0.99) (P = 0.014) (4469 events) for cardiovascular disease, 0.89 (0.85, 0.93) (P < 0.0001) (2132 events) for respiratory disease, 0.89 (0.81, 0.98) (P = 0.012) (563 events) for fractures, and 1.02 (0.99, 1.06) (P = 0.21) (3121 events) for incident total cancers.

Conclusions: Plasma 25(OH)D concentrations predict subsequent lower 13-y total mortality and incident cardiovascular disease, respiratory disease, and fractures but not total incident cancers. For mortality, lowest risks were in subjects with concentrations >90 nmol/L, and there was no evidence of increased mortality at high concentrations, suggesting that a moderate increase in population mean concentrations may have potential health benefit, but <1% of the population had concentrations >120 nmol/L. Am J Clin Nutr 2014;100:1361–70.

INTRODUCTION

Vitamin D deficiency is a well-established cause of impaired bone mineralization that leads to conditions such as rickets and osteomalacia. In addition, vitamin D status has been associated with other health outcomes including osteoporotic fractures, cardiovascular disease, cancers, diabetes, respiratory diseases, and all-cause mortality (1–17). However, substantial debate continues as to what an optimal vitamin D status might be above low blood concentrations associated with deficiency bone diseases (1), and randomized trials of vitamin D supplementation have not provided conclusive evidence (1, 2, 5). An understanding of the dose-response relation between serum vitamin D concentrations in a general population of men and women and a range of health outcomes may help our understanding of how vitamin D may relate to health and inform future trial designs or public health recommendations.

SUBJECTS AND METHODS

Participants were recruited from age-sex registers of general practices for a prospective population study of 25,639 men and women aged 40–79 y, 99.5% of whom were white, who were residents in Norfolk, United Kingdom, and first surveyed in 1993–1997 as part of the 10-country collaboration the European Prospective Investigation into Cancer and Nutrition (18).

Between 1997 and 2000, ~15,000 participants attended a second clinic visit (19). At this visit, participants completed a detailed health and lifestyle questionnaire. A personal medical history of heart attack, stroke, cancer, asthma, bronchitis, and fractures; smoking history; alcohol intake; supplement use; physical activity; social class; and educational status were ascertained by using standard questionnaires (19–21). Participants were asked about their medical histories with the question “Has a doctor ever told you that you have any of the following?”

1 From the Department of Public Health and Primary Care, Institute of Public Health, School of Clinical Medicine (K-TK and RL) and the Medical Research Council Epidemiology Unit (NW), University of Cambridge, Cambridge, United Kingdom.

2 Sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of data; or preparation, review, or approval of the manuscript.

3 European Prospective Investigation into Cancer–Norfolk is supported by program grants from the Medical Research Council UK (G1000143) and Cancer Research UK (14136). This is an open access article distributed under the CC-BY license (http://creativecommons.org/licenses/by/3.0/).

4 Address correspondence to K-T Khaw, Clinical Gerontology Unit Box 251, University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom. E-mail: kk101@medschl.cam.ac.uk.

Received February 21, 2014. Accepted for publication August 13, 2014. First published online September 17, 2014; doi: 10.3945/ajcn.114.086413.

Am J Clin Nutr 2014;100:1361–70. Printed in USA.
followed by a list of conditions that included heart attack, stroke, cancer, asthma, bronchitis, and fractures. Prevalent conditions were defined as yes answers to the relevant condition. Smoking history was derived from yes or no responses to the questions “Have you ever smoked as much as one cigarette a day for as long as a year?” and “Do you smoke cigarettes now?” Alcohol consumption was derived from the question “How many alcoholic drinks do you have each week?” with 4 separate categories of drinks. A unit of alcohol (~8 g) was defined as a half-pint of beer, cider, or lager; a glass of wine; a single unit of spirits (whisky, gin, brandy, or vodka); or a glass of sherry, port, vermouth, or liqueurs. Total alcohol consumption was estimated as the total units of drinks consumed in a week. Supplement use was ascertained by using the question “Have you taken any vitamins, minerals, or other food supplements regularly during the past year (such as vitamin C, vitamin D, iron, calcium, fish oils, primrose oil, betacarotene, etc)?” Habitual physical activity was assessed by using 2 questions about occupational and other physical activity, and individuals were allocated to a physical activity index validated against heart-rate monitoring in one of 4 categories as follows: inactive, moderately inactive, moderately active, and active (21).

Social class was classified according to the Registrar General’s occupation-based classification scheme into 5 main categories with social class I representing professionals, social class II representing managerial and technical occupations, social class III representing subdivision into nonmanual and manual skilled workers, social class IV representing partly skilled workers, and social class V representing unskilled manual workers. We also recategorized social class into manual and nonmanual social classes. Social classes I–II nonmanual were classified as nonmanual, whereas social classes III manual, IV, and V were classified as manual (20). Educational status was based on the highest qualification attained and was categorized into 4 groups as follows: degree or equivalent, A-level or equivalent, O-level or equivalent, and less than O-level or no qualifications. O-level indicates educational attainment to the equivalent of completion of schooling to the age of 15 y, and A-level indicates educational attainment to the equivalent of the completion of schooling to the age of 17 y. Educational level was categorized into “at least O-level” (which includes O-level, A-level, and degree) and “no qualifications” (20).

Individuals with prevalent conditions were identified if they answered yes to the question “Have you been diagnosed by a doctor as having any of the following conditions? followed by a checklist of the individual conditions previously listed and a box for filling in dates and more details. Dietary intake was assessed by using a mailed food-frequency questionnaire and analyzed for nutrient intake including dietary calcium (22).

Trained nurses carried out a health examination. BMI (in kg/m²) was estimated as weight divided by the square of height. Plasma and serum samples were obtained from venipuncture blood samples. The plasma vitamin C concentration as a biomarker of plant food intake was estimated by using a fluorometric assay (23, 24). Samples were stored frozen in liquid nitrogen tanks until 2012 when serum samples were retrieved for 25-hydroxyvitamin D (25(OH)D) assays. Assays were conducted by VITAS, which is a reference laboratory in Nordic countries for fat soluble vitamins (25–27). Assays for 25(OH)D were based on ultraperformance liquid chromatography interfaced by atmospheric pressure chemical ionization to mass spectrometry. This method measures the C3 epimer 3-epi-25(OH)D3 as well as 25(OH)D3 and 25(OH)D2. The limit of detection is 1–4 nmol/L. CVs for interassay analyses are 7.6% at 25(OH)D concentrations of 47.8 nmol/L and 6.9% at 83.0 nmol/L.

All participants were followed up for health events. We report results for follow-up to December 2012 (an average of 13 y). All participants were flagged for death certification at the Office of National Statistics, United Kingdom. Death certificates were coded by nosologists according to the International Classification of Diseases (ICD). An underlying cause of death was defined by using ICD codes as follows: for cardiovascular death (ICD9 400–438 or ICD10 I10–I79), cancer death (ICD9 140–208 or ICD10 C00–C97), or respiratory disease (ICD9 460–519 or ICD10 J00–J99). We also examined specifically the following 2 subgroups: chronic respiratory disease ICD9 490–496 or ICD10 J40–J47 and respiratory infections ICD9 466 and 480–487 or ICD10 J10–J22 and J85. Deaths that were not attributable to underlying cardiovascular, respiratory, or cancer causes were classified as deaths from other causes. All participants are also linked to the National Cancer Registry for incident cancers. Participants admitted to hospital were identified by their unique national health service number by using data linkage with ENCORE (East Norfolk Health Authority database), which identifies all hospital contacts throughout England and Wales for Norfolk residents. We used diagnostic codes to ascertain dates of first-incident hospital admissions for cardiovascular diseases, respiratory diseases, and fractures. We analyzed data according to deaths by underlying cause and total incident fatal and nonfatal diseases, which were defined as either death or hospital admission for the relevant condition, which is an approach that was previously validated for cardiovascular conditions by using medical records. The study was approved by the Norwich District Health Authority Ethics Committee, and all participants gave signed informed consent.

The current analysis included 14,641 men and women aged 42–82 y who attended the second health examination in 1997–2000 and had available blood samples for assays. Total 25(OH)D was calculated as the sum of 25(OH)D3 and 25(OH)D2. Where concentrations of 25(OH)D2 were below limits of detection (1 nmol/L), they were coded as zero. We categorized total 25(OH)D into 5 categories by using clinically relevant cutoffs as follows: <30, 30 to <50, 50 to <70, 70 to <90, and ≥90 nmol/L (multiply by 0.4 to get ng/mL).

We examined risk-factor distributions in men and women by 25(OH)D category. Concentrations of 25(OH)D showed marked seasonal variations, and thus, all results were adjusted for the month of assessment. The Cox proportional hazards model was used to determine RRs of all-cause and cause-specific mortality, incident cancers, and total fatal and nonfatal incident cardiovascular disease, respiratory diseases, and fractures by plasma 25(OH)D category after adjustment for age, sex, and month and then further adjustment for BMI, cigarette-smoking habit, alcohol intake, physical activity, plasma vitamin C, social class, education, and history of cardiovascular disease, cancer, or diabetes. We estimated HRs for all-cause mortality, incident total cancers, and incident chronic disease hospitalizations by using plasma vitamin D as a continuous variable per 20-nmol/L increase. We also examined RRs in subgroups stratified by sex, age
group, BMI, manual and nonmanual social classes, smoking status, physical activity, and any supplement use and after the exclusion of individuals with any history of cardiovascular disease, diabetes, cancer, fractures, or respiratory diseases and those who died within ≤2 or ≤5 y of follow-up. We compared mean baseline 25(OH)D concentrations by the month of assessment in subjects who survived and those who died. To enable the categorization of individuals by taking into account the seasonal variation, we estimated coefficients according to the month of blood draw in relation to the estimate in November, which was the month that most closely approximated the overall individual annual mean.

We also compared survival curves in individuals with concentrations >120 nmol/L to examine mortality in subjects with highest vitamin D concentrations in this cohort although they accounted for only 1% of the total cohort. Only 21 individuals (0.1%) had 25(OH)D concentrations >150 nmol/L, and 2 individuals had 25(OH)D concentrations >80 nmol/L in this cohort.

**RESULTS**

Of 14,641 individuals with 25(OH)D3 results, only 925 individuals had measurable 25(OH)D2 concentrations, and 8736 individuals had measurable 3-epi-25(OH)D3 concentrations. Population mean concentrations were 56.2 nmol/L (range: 3.4–201.9 nmol/L) for 25(OH)D3, 0.35 nmol/L (5.6 nmol/L in those with detectable concentrations) (range: 0–82.5 nmol/L) for 25(OH)D2, and 1.36 nmol/L (2.3 nmol/L in those with detectable concentrations) (range: 0–46.3 nmol/L) for 3-epi-25(OH)D3. The total 25(OH)D concentration, which was calculated as the sum of 25(OH)D3 and 25(OH)D2, had a mean of 56.6 nmol/L (range: 4.6–201.9 nmol/L) with 25(OH)D3 contributing 99% of the plasma total, and 25(OH)D2 contributing 1% of the plasma total.

Characteristics of participants by 25(OH)D category measured in 1997–2000 are shown in Table 1. In this cohort, 9% of men and 13% of women had concentrations <30 nmol/L, and 9% of men and 8% of women had concentrations ≥90 nmol/L. Plasma 25(OH)D concentrations were inversely related to BMI, current smoking status, and physical inactivity and positively related to lung function and blood vitamin C concentrations.

Mortality rates from 1997 to 2000 and HRs by plasma 25(OH)D category by cause adjusted for age, sex, and month of blood draw and additionally adjusted for BMI, cigarette smoking, physical activity, alcohol intake, plasma vitamin C, social class, education, diabetes, history of cardiovascular disease, and history of cancer are shown in Table 2. HRs for incident total cancer, incident cardiovascular diseases, respiratory diseases, total fractures, and hip fractures adjusted first for age, sex, and month and further multivariable adjusted as described previously are also shown in Table 2. There was a strong inverse association between increasing 25(OH)D category and total mortality with individuals with concentrations ≥90 nmol/L having 34% lower risk of mortality compared than for subjects with concentrations <30 nmol/L. There appeared to be a graded relation across the distribution of vitamin D concentrations. Trends were apparent for deaths from cardiovascular causes and respiratory disease causes with the greatest magnitude of difference for respiratory causes but not significant for deaths from cancer or other non-cardiovascular nonrespiratory underlying causes. When analyzed as a continuous variable, for every 20-nmol/L increase in 25(OH)D, there was 11% lower cardiovascular disease mortality risk and 30% lower respiratory disease mortality risk. These associations only slightly attenuated after multivariable adjustment.

Consistent with the mortality findings, baseline 25(OH)D concentrations were not significantly associated with cancer incidence but were inversely associated with incident total cardiovascular disease and respiratory disease with the greatest magnitude of association observed for respiratory diseases. Concentrations of 25(OH)D were also significantly inversely associated with incident fractures and hip fractures although less apparently linearly with the lower RR flattening at concentrations >50 nmol/L.

HRs for total mortality per increase of 20 nmol/L serum 25(OH)D, which were consistent in the various subgroups examined, including stratification by dietary calcium intake and also apparent after the exclusion of individuals with prevalent diseases or individuals who died ≥2 or ≤5 y follow-up are shown in Table 3.

Mean baseline vitamin D concentrations by the month of blood draw in 1993–1997 in individuals who were dead compared with those who were alive at the end of follow-up in 2012 are shown in Figure 1. Despite a substantial seasonal variation in mean vitamin D concentrations, there was a consistent difference throughout the months between individuals who died and those who survived over the 13 subsequent years of follow-up. Coefficients for the month of blood draw to obtain the estimated mean annual vitamin D for categorizing individuals are presented in the figure legend.

We previously reported an association between 25(OH)D concentrations and incident diabetes on the basis of a nested case-control design by using blood samples from the 1993–1997 baseline survey taken 4 y before the current study (8). The 25(OH)D assays for this earlier analysis were undertaken in a different laboratory by using different methods. Nevertheless, in 877 individuals with available vitamin D measures in both 1993–1997 and 1997–2000, there was a correlation of 0.36 ($P < 0.001$) between the 2 independent samples. After adjustment for the month of blood draw at both visits by using the coefficients shown in Figure 1, the correlation was 0.45 ($P < 0.001$).

Only 2 individuals had 25(OH)D concentrations >180 nmol/L (>72 ng/mL), which is the recommended upper limit. There were no deaths that occurred in this group. We recategorized the cohort according to new cutoffs with an upper group of ≥120 nmol/L (48 ng/mL) to explore the association with mortality at the higher concentrations of 25(OH)D although numbers were small in this high category (n = 152; 1% of the total cohort). Survival curves over follow-up between 1997 and 2012 are shown in Figure 2. Age-, sex-, and month-adjusted HRs (95% CIs) for cutoffs <30, 30 to <90, 90 to <120, and ≥120 nmol/L were 1.07 (0.69, 0.98), 0.68 (0.56, 0.83), and 0.53 (0.33, 0.87), respectively. Analyses conducted by using only 25(OH)D3 rather than total 25(OH)D showed essentially similar results.

**DISCUSSION**

In these middle-aged and older men and women, plasma 25(OH)D concentrations measured between 1997 and 2000 were inversely associated with total mortality over an average of 13 y
Men

| Category | n  | 25(OH)D (nmol/L) | Vitamin C (nmol/L) | Serum 25(OH)D concentrations | Serum 25(OH)D concentrations |
|----------|----|-----------------|--------------------|-----------------------------|-----------------------------|
|          |    | Total 25(OH)D   | 40.2 ± 5.9         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 59.0 ± 5.9         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | 25(OH)D2        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | 3-epi-25(OH)D   | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Age (y)         | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | BMI (kg/m²)     | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Systolic blood  | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | pressure (mm Hg)| 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Cholesterol     | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (mmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Respiratory     | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | function FEV1  | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (l/s)           | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Vitamin C       | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Serum 25(OH)D   | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | concentrations  | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | 25(OH)D2        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | 3-epi-25(OH)D   | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Age (y)         | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | BMI (kg/m²)     | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Systolic blood  | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | pressure (mm Hg)| 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Cholesterol     | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (mmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Respiratory     | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | function FEV1  | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (l/s)           | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Vitamin C       | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Serum 25(OH)D   | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | concentrations  | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | 25(OH)D2        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | 3-epi-25(OH)D   | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | (nmol/L)        | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Age (y)         | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | BMI (kg/m²)     | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | Systolic blood  | 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |
|          |    | pressure (mm Hg)| 25.0 (131)         | 25.0 (131)                  | 25.0 (131)                  |

Comparison of means and 95% confidence intervals. Differences between means were compared using the Student’s t-test (for two groups) or analysis of variance (ANOVA) with the Bonferroni correction for multiple comparisons. Differences at p < 0.01 were considered statistically significant. Six hundred forty-eight men and 8,155 women were in the EPIC-Norfolk 1997–2000 by serum 25(OH)D (total of and 25(OH)D2 and 25(OH)D3). (See Table 1.)

Of follow-up. There appeared to be a dose-response relation across the whole distribution of 25(OH)D concentrations with the lowest mortality observed in the category with blood concentrations >90 nmol/L. Approximately 10% of the population had concentrations <30 nmol/L, 9% of the population had concentrations >90 nmol/L, and 1% of the population had concentrations >120 nmol/L. This inverse association was consistent after adjustment for age, sex, month of blood draw, BMI, physical activity, smoking, alcohol intake, plasma vitamin C concentrations, occupational social class, education, diabetes history, history of cardiovascular disease, and history of cancer. This association was also consistent in subgroups after
| Serum 25(OH)D category (nmol/L) | <30 (n = 1640) | 30 to <50 (n = 4546) | 50 to <70 (n = 4702) | 70 to <90 (n = 2580) | ≥90 (n = 1173) | HR (95% CI) per 20-nmol/L increase in serum 25(OH)D | P-linear trend |
|--------------------------------|----------------|---------------------|---------------------|---------------------|----------------|-----------------------------------------------|--------------|
| Deaths: all causes             |                |                     |                     |                     |                |                                               |              |
| % (n)                          | 24.2 (397)     | 21.2 (966)          | 17.7 (834)          | 16.1 (416)          | 13.9 (163)     | —                                             | <0.0001      |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.84 (0.74, 0.94)  | 0.72 (0.63, 0.81)  | 0.71 (0.62, 0.82)  | 0.66 (0.55, 0.79) | 0.89 (0.86, 0.93) | <0.0001      |
| Deaths from cardiovascular causes |            |                     |                     |                     |                |                                               |              |
| % (n)                          | 7.7 (126)      | 6.8 (308)           | 5.4 (254)           | 4.7 (121)           | 3.8 (45)       | —                                             | <0.0001      |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.86 (0.70, 1.06)  | 0.72 (0.58, 0.90)  | 0.70 (0.54, 0.91)  | 0.62 (0.44, 0.88) | 0.88 (0.83, 0.94) | <0.0001      |
| Deaths from cancer causes      |                |                     |                     |                     |                |                                               |              |
| % (n)                          | 7.7 (126)      | 8.3 (376)           | 7.0 (331)           | 6.9 (179)           | 6.3 (74)       | —                                             | 0.014         |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.97 (0.79, 1.19)  | 0.85 (0.79, 1.05)  | 0.86 (0.68, 1.09)  | 0.85 (0.62, 1.09) | 0.93 (0.88, 0.99) | <0.0001      |
| Deaths from respiratory causes |                |                     |                     |                     |                |                                               |              |
| % (n)                          | 3.4 (56)       | 1.8 (81)            | 1.3 (60)            | 1.2 (30)            | 0.7 (8)        | —                                             | <0.0001      |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.47 (0.34, 0.67)  | 0.34 (0.24, 0.50)  | 0.35 (0.22, 0.56)  | 0.22 (0.10, 0.46) | 0.70 (0.62, 0.81) | <0.0001      |
| Deaths from other causes       |                |                     |                     |                     |                |                                               |              |
| (noncardiovascular, noncancer, and nonrespiratory) | | | | | | | |
| % (n)                          | 5.4 (89)       | 4.4 (201)           | 4.0 (189)           | 3.3 (86)            | 3.1 (36)       | —                                             | <0.0001      |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.79 (0.61, 1.01)  | 0.70 (0.57, 0.96)  | 0.69 (0.51, 0.94)  | 0.69 (0.46, 1.02) | 0.91 (0.84, 0.99) | 0.02         |
| All cancer incidence           |                |                     |                     |                     |                |                                               |              |
| % (n)                          | 21.0 (345)     | 22.0 (999)          | 21.2 (996)          | 21.2 (546)          | 20.0 (235)     | —                                             | 0.35         |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.97 (0.86, 1.10)  | 0.95 (0.84, 1.08)  | 1.05 (0.91, 1.20)  | 1.00 (0.85, 1.19) | 1.01 (0.97, 1.04) | 0.77         |
| Cardiovascular disease events  |                |                     |                     |                     |                |                                               |              |
| % (n)                          | 36.2 (593)     | 3331 (1561)         | 29.2 (1372)         | 27.3 (704)          | 24.2 (284)     | —                                             | <0.0001      |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.91 (0.82, 0.99)  | 0.80 (0.73, 0.89)  | 0.78 (0.70, 0.87)  | 0.75 (0.70, 0.88) | 0.92 (0.90, 0.95) | <0.0001      |
| Respiratory disease events     |                |                     |                     |                     |                |                                               |              |
| % (n)                          | 21.0 (345)     | 15.8 (718)          | 13.2 (621)          | 12.4 (321)          | 10.8 (127)     | —                                             | <0.0001      |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.72 (0.63, 0.82)  | 0.59 (0.51, 0.68)  | 0.57 (0.48, 0.67)  | 0.55 (0.44, 0.68) | 0.85 (0.82, 0.90) | <0.0001      |
| All fracture events            |                |                     |                     |                     |                |                                               |              |
| % (n)                          | 5.4 (89)       | 4.2 (189)           | 3.5 (165)           | 3.3 (86)            | 2.9 (34)       | —                                             | <0.0001      |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.77 (0.59, 0.99)  | 0.68 (0.52, 0.90)  | 0.65 (0.47, 0.89)  | 0.62 (0.40, 0.95) | 0.88 (0.81, 0.96) | 0.002        |
| HR (95% CI)                    | 1.00 (1.00, 1.00) | 0.78 (0.58, 1.05)  | 0.70 (0.51, 0.95)  | 0.65 (0.45, 0.93)  | 0.64 (0.40, 1.03) | 0.89 (0.81, 0.97) | 0.012        |

(Continued)
| Serum 25(OH)D category (nmol/L) | Hip-fracture events |
|---------------------------------|---------------------|
| <30 (n = 1640)                  | 2.2 (36)            |
| 30 to <50 (n = 4546)            | 1.6 (72)            |
| 50 to <70 (n = 2580)            | 1.2 (58)            |
| 70 to <90 (n = 1173)            | 0.7 (19)            |
| ≥90 (n = 1173)                  | 0.6 (13)            |

Conversion factors for nanomoles per liter to nanograms per milliliter were as follows: for 25(OH)D 3, divide nanomoles per liter by 2.496 to obtain nanograms per milliliter; for 25(OH)D 2, divide nanomoles per liter by 2.42 to obtain nanograms per milliliter. As a general approximation, multiply nanomoles per liter by 0.4 to obtain nanograms per milliliter (30 nmol/L = 12 ng/mL, 50 nmol/L = 20 ng/mL, 70 nmol/L = 28 ng/mL, 90 nmol/L = 36 ng/mL, and 120 nmol/L = 48 ng/mL).

**TABLE 2 (Continued)**

| Serum 25(OH)D category (nmol/L) | Hip-fracture events |
|---------------------------------|---------------------|
| <30 (n = 1640)                  | 2.2 (36)            |
| 30 to <50 (n = 4546)            | 1.6 (72)            |
| 50 to <70 (n = 2580)            | 1.2 (58)            |
| 70 to <90 (n = 1173)            | 0.7 (19)            |
| ≥90 (n = 1173)                  | 0.6 (13)            |

**TABLE 2 (Continued)**

| Serum 25(OH)D category (nmol/L) | Hip-fracture events |
|---------------------------------|---------------------|
| <30 (n = 1640)                  | 2.2 (36)            |
| 30 to <50 (n = 4546)            | 1.6 (72)            |
| 50 to <70 (n = 2580)            | 1.2 (58)            |
| 70 to <90 (n = 1173)            | 0.7 (19)            |
| ≥90 (n = 1173)                  | 0.6 (13)            |

Stratification for age, sex, smoking status, BMI, physical activity, any vitamin supplement use, social class, and dietary calcium intake and after exclusions of individuals with prevalent chronic diseases and deaths within the first 5 y. Across the observed range of 25(OH)D concentrations in this cohort, each increase of 20 nmol/L in blood concentrations was associated with ~8% lower observed mortality risk over the 13 y follow-up. The association was strongest for mortality from respiratory diseases. Plasma 25(OH)D was also inversely associated with incident cardiovascular disease and respiratory disease and also for total fractures and hip fractures. Again, strongest associations were observed for respiratory diseases. Plasma 25(OH)D was not associated with total cancer incidence.

Substantial debate continues as to what optimal vitamin D status might be above low blood concentrations associated with deficiency and bone diseases. An Institute of Medicine report set serum 25(OH)D cutoffs of increased risk of deficiency at <30 nmol/L, adequacy at >50 nmol/L, and increased risk of excess at >125 nmol/L on the basis of reviews that suggested a reverse J curve for overall mortality with highest risk from low vitamin D (<30 nmol/L), lower risk between vitamin D concentrations of 30–60 nmol/L, with risk increasing again at higher concentrations (>75 nmol/L) in whites and >60 nmol in African Americans and adverse outcomes with serum 25(OH)D concentration >125 nmol/L (1). Although the European Society for Clinical and Economic Aspects of Osteoporosis and Arthritis stated that, above a serum threshold of 50 nmol/L for 25(OH)D concentrations, there is no clear evidence for additional benefits of supplementation, they indicated that, in fragile elderly subjects at elevated risk of falls and fractures, a minimal serum 25(OH)D concentration of 75 nmol/L is recommended (28).

Randomized clinical trials of vitamin D supplementation have not provided conclusive evidence. A review of 56 randomized trials with 95286 participants that examined vitamin D at any dose, duration, and route of administration observed that vitamin D in the form of vitamin D3 seems to decrease mortality in predominantly elderly women who are mainly in institutional care but otherwise concluded that the available evidence on vitamin D supplementation and mortality is inconclusive (2). A similar debate applies to vitamin D–supplementation trials for prevention of fractures, cardiovascular disease, and other health outcomes (1, 2, 5, 16, 29–33).

Some of the uncertainty has been attributed variously to the heterogeneity in the baseline vitamin D status of the populations studied, uncertain compliance, different modes of administration of vitamin D because oral compared with intramuscular administration or small daily doses compared with infrequent bolus doses result in very different blood concentrations (34), different forms of vitamin D administered because different isomers such as cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2) are postulated to have different biological potency and effects (35), possible interactions with other nutrients such as dietary or supplemental calcium (7), and low power for mortality. Many trials have focused on high-risk groups such as trials of the prevention of fractures in the very old or individuals with osteoporosis, and the largest trial to date, the Women’s Health Initiative, was conducted only in postmenopausal women (33).

Observational studies, particularly cohort studies, may be better placed to quantify the association between vitamin D and health outcomes, but results have also been inconsistent (14, 36).
Vitamin D is manufactured in the skin in the presence of sunlight, and thus, blood concentrations rather than the assessment of dietary intake provide the most accurate assessment of individual vitamin D status. Hitherto, the assay of 25(OH)D concentrations in large-population cohorts has been challenging for reasons of cost and assay variations. Many assays have not distinguished between the various isomers of vitamin D such as 25(OH)D₃, 25(OH)D₂, and the C3 epimer 3-epi-25(OH)D₃ (37) and variations in assay methods make the interpretation of and comparisons between studies difficult (38). Nevertheless a systematic review of 12 prospective studies in 32142 individuals of whom 6921 died during follow-up showed an inverse association between 25(OH)D and all-cause mortality (14). The meta analysis estimated a pooled HR of 0.92 (95% CI: 0.89, 0.95) for a 25-nmol/L increase in 25(OH)D concentrations, which is an estimate that is remarkably similar to that observed in the current single cohort of 14,679 individuals with 2780 deaths. These results are also compatible with results from a 5-y vitamin D₃-supplement randomized trial with means of 74.3 compared with 53.4 nmol/L in vitamin D-supplement and placebo groups, respectively, resulting in a mean difference of ~21 nmol/L and a nonsignificant RR of 0.88 (95% CI: 0.74, 1.06; \( P = 0.18 \)) of mortality in supplement compared with placebo groups (39).

We also showed strong inverse associations of serum 25(OH)D with incident and fatal cardiovascular disease, respiratory disease, and fractures. Although these associations have been variably documented previously (6, 11, 13, 40–43), the dose-response relation between plasma 25(OH)D concentrations and health

**TABLE 3**

|                          | HR (95% CI) per 20-nmol/L increase in serum 25(OH)D (age, sex, and month adjusted) | P       | HR (95% CI) per 20-nmol/L increase in serum 25(OH)D (age, sex, month, and multivariable adjusted)² | P       |
|--------------------------|-----------------------------------------------------------------------------------|---------|-------------------------------------------------------------------------------------------------|---------|
| All                      | 0.89 (0.86, 0.93)                                                                | <0.0001 | 0.92 (0.88, 0.96)                                                                                | <0.0001 |
| By sex                   |                                                                                   |         |                                                                                                 |         |
| Men                      | 0.89 (0.85, 0.94)                                                                | <0.0001 | 0.92 (0.87, 0.97)                                                                                | 0.001   |
| Women                    | 0.89 (0.84, 0.94)                                                                | <0.0001 | 0.92 (0.86, 0.98)                                                                                | 0.011   |
| By age                   |                                                                                   |         |                                                                                                 |         |
| <65 y                    | 0.88 (0.81, 0.94)                                                                | <0.0001 | 0.92 (0.85, 0.99)                                                                                | 0.038   |
| ≥65 y                    | 0.90 (0.86, 0.94)                                                                | <0.0001 | 0.92 (0.88, 0.97)                                                                                | 0.001   |
| Excluding early deaths   |                                                                                   |         |                                                                                                 |         |
| Excluding deaths ≤2 y    | 0.90 (0.87, 0.93)                                                                | <0.0001 | 0.92 (0.89, 0.97)                                                                                | <0.0001 |
| Excluding deaths ≥5 y    | 0.91 (0.88, 0.95)                                                                | <0.001  | 0.94 (0.89, 0.98)                                                                                | <0.001  |
| By smoking status        |                                                                                   |         |                                                                                                 |         |
| Current smokers          | 0.89 (0.81, 0.98)                                                                | 0.018   | 0.90 (0.80, 1.01)                                                                                | 0.066   |
| Current nonsmokers       | 0.91 (0.87, 0.94)                                                                | <0.0001 | 0.93 (0.89, 0.97)                                                                                | 0.001   |
| By BMI                   |                                                                                   |         |                                                                                                 |         |
| <27 kg/m²                | 0.89 (0.85, 0.94)                                                                | <0.0001 | 0.92 (0.87, 0.97)                                                                                | 0.002   |
| ≥27 kg/m²                | 0.91 (0.86, 0.96)                                                                | <0.001  | 0.93 (0.88, 0.99)                                                                                | 0.030   |
| By physical activity     |                                                                                   |         |                                                                                                 |         |
| Physically inactive      | 0.88 (0.83, 0.93)                                                                | <0.0001 | 0.90 (0.84, 0.97)                                                                                | 0.003   |
| Not physically inactive  | 0.92 (0.88, 0.96)                                                                | <0.001  | 0.94 (0.89, 0.98)                                                                                | 0.009   |
| Excluding persons with a history of heart disease, stroke, cancer, diabetes, or fracture | 0.90 (0.86, 0.93) | <0.001 | 0.92 (0.88, 0.96) | <0.001 |
| Excluding persons with history of asthma or bronchitis | 0.90 (0.87, 0.93) | <0.0001 | 0.92 (0.89, 0.96) | <0.001 |
| By social class          |                                                                                   |         |                                                                                                 |         |
| Nonmanual social class   | 0.88 (0.84, 0.93)                                                                | <0.0001 | 0.91 (0.86, 0.95)                                                                                | <0.0001 |
| Manual social class      | 0.92 (0.87, 0.98)                                                                | 0.008   | 0.95 (0.88, 1.01)                                                                                | 0.12    |
| By vitamin supplement use|                                                                                   |         |                                                                                                 |         |
| No vitamin supplement use| 0.91 (0.86, 0.96)                                                                | <0.0001 | 0.92 (0.86, 0.98)                                                                                | 0.007   |
| Any vitamin supplement use| 0.90 (0.85, 0.95)                                                                | <0.0001 | 0.93 (0.87, 0.98)                                                                                | 0.010   |
| By dietary calcium intake|                                                                                   |         |                                                                                                 |         |
| <1000 mg/d               | 0.91 (0.86, 0.96)                                                                | 0.02    | 0.93 (0.87, 0.99)                                                                                | 0.02    |
| ≥1000 mg/d               | 0.88 (0.84, 0.93)                                                                | <0.0001 | 0.91 (0.86, 0.97)                                                                                | 0.004   |

¹ Conversion factors for nanomoles per liter to nanograms per milliliter were as follows: for 25(OH)D₃, divide nanomoles per liter by 2.496 to obtain nanograms per milliliter; for 25(OH)D₂, divide 25(OH)D₂ by 2.42 to obtain nanograms per milliliter. As a general approximation, multiply nanomoles per liter by 0.4 to obtain nanograms per milliliter (30 nmol/L = 12 ng/mL, 50 nmol/L = 20 ng/mL, 70 nmol/L = 28 ng/mL, 90 nmol/L = 36 ng/mL, and 120 nmol = 48 ng/mL).

² Further adjusted for BMI, cigarette smoking, alcohol intake, plasma vitamin C, physical activity, diabetes, history of cardiovascular disease, history of cancer, social class, and educational level (except where the variable was used for stratification). Numbers do not always add up to total because of missing data.
isomers. With the use of a high-sensitivity assay, the predominant purposes in this UK population.

Month of blood draw outlined in Figure 1 is adequate for these algorithms of varying complexity have been proposed (44); our individual’s usual vitamin D status is challenging, and various associations with endpoints.

from intraindividual variation was likely to have attenuated any concentrations throughout the year. A random measurement error of follow-up showed consistent significant differences in mean concentrations by the baseline month of blood draw to characterize the individual annual mean were as follows: Jan, +9; Feb, +11; Mar, +11; Apr, +6; May, +3; June, −4; July, −5; Aug, −12; −Sep, −11; Oct, −5; Nov, (mean); Dec, +2. 25(OH)D, 25-hydroxyvitamin D.

outcomes and the nature of the relationship, whether threshold or U-shaped, are still debated. This study, which included men and women, enabled the examination of the dose-response relation with total mortality at concentrations >90 and >120 nmol/L although with only a small proportion of the population with concentrations >120 nmol/L (n = 152; 1%) and >150 nmol/L (n = 21; 0.1%); we did not have power to assess potential adverse outcomes above concentrations of 150 nmol/L. Nevertheless, mean 25(OH)D distributions and seasonal variations were broadly comparable to those noted for other Northern hemisphere countries, most notably in the US NHANES III.

The significant relations were somewhat surprising because only one measure of 25(OH)D was used to characterize individual status, and large seasonal variations in 25(OH)D concentrations have been well established. Nevertheless, comparisons of mean vitamin D concentrations by the baseline month of blood draw in subjects who survived and those who were alive after 13 y of follow-up showed consistent significant differences in mean concentrations throughout the year. A random measurement error from intraindividual variation was likely to have attenuated any associations with endpoints.

Because of the large seasonal variation, characterizing an individual’s usual vitamin D status is challenging, and various algorithms of varying complexity have been proposed (44); our data suggested that a simple adjustment on the basis of the month of blood draw outlined in Figure 1 is adequate for these purposes in this UK population.

Many assays do not distinguish between various 25(OH)D isomers. With the use of a high-sensitivity assay, the predominant form of vitamin D was vitamin D₃ (97%), and the other isomers 25(OH)D₂ and 3-epi-25(OH)D₃ only contributed a small proportion. Main results are shown for total 25(OH)D but were very similar for 25(OH)D₃ alone. We were unable to assess whether 25(OH)D₃ derived from ergocalciferol would have similar associations.

Incident diseases were ascertained from mortality and hospital-admission data, which in the United Kingdom with the National Health Service are virtually complete. Validation studies on the basis of medical records have shown good validation for cardiovascular diseases. However, milder nonfatal cases that did not require a hospital admission would have been missed. Although this absence may have limited the generalizability of results to more-severe diseases, it is likely that a measurement error in disease ascertainment would have attenuated associations.

In conclusion, this 13-y prospective study in a free-living, middle-aged and older British population provides additional support for the hypothesis that vitamin D status is associated with a range of important health outcomes including respiratory disease, cardiovascular disease, fractures, and total mortality. Highest mortality rates were observed in individuals with 25(OH)D concentrations <30 nmol/L. Negligible numbers of subjects had concentrations >150 nmol/L, and only 1% of the population had concentrations >120 nmol/L. Within this observed population range, there was no evidence for increased mortality for 25(OH)D >90 or >120 nmol/L, suggesting that a moderate increase in population mean concentrations may have a potential health benefit for preventing deficiency without increasing risk.

The authors’ responsibilities were as follows—K-TK and NW: were principal investigators in the European Prospective Investigation into Cancer and Nutrition–Norfolk population study; RL: was responsible for data management, record linkage, and computing; K-TK: conducted data analyses; was the guarantor and took responsibility for the integrity of the data and the data analysis; and affirmed that the manuscript was an honest, accurate, and transparent account of the study being reported, that no important aspects of the study were omitted, and that any discrepancies from the study as planned (and, if relevant, registered) were explained; and all authors: had

FIGURE 1. Mean serum 25(OH)D concentrations by month at the 1997–2000 baseline examination in subjects alive and subjects dead at follow-up in 2012. The mean difference in baseline 25(OH)D concentrations in subjects alive compared with subjects dead in 2012, adjusted by age, sex, and month was +3.8 nmol/L (P < 0.0001). Estimated coefficients in nanomoles per liter to add to 25(OH)D concentration in nanomoles per liter to adjust for the month of blood draw to characterize the individual annual mean were as follows: Jan, +9; Feb, +11; Mar, +11; Apr, +6; May, +3; June, −4; July, −5; Aug, −12; −Sep, −11; Oct, −5; Nov, (mean); Dec, +2. 25(OH)D, 25-hydroxyvitamin D.

FIGURE 2. Survival between 1997 and 2012 by serum 25-hydroxyvitamin D category in men and women with adjustment for age, sex, and month.
access to data and wrote the manuscript. None of the authors had a conflict of interest. The authors declare no support from any commercial organization for the submitted work.

REFERENCES

1. Institute of Medicine. Ross AC, Taylor CL, Yaktine AL, del Valle H, eds. Dietary Reference Intakes for calcium and vitamin D, 2011.

2. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wettesljer J, Simonetti RG, Bjelakovic M, Gluud C. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database Syst Rev 2014;1:CD007470.

3. Auvert P, Boniol M, Pizot C, Mullie P, Vitamin D and ill health: a systematic review. Lancet Diabetes Endocrinol 2014;2:76–89.

4. Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, Flicker L, Wark J, Jackson RD, Cauley JA, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012;367:40–9. (Published erratum appears in N Engl J Med 2012;367:481.)

5. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury RJ, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury RJ. Vitamin D and cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality—a review of recent evidence. Autoimmun Rev 2013;12:976–89.

6. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB. Vitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab 2010;95:2637–45.

7. DIPART Group. Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe. BMJ 2010;340:b5463.

8. Forouhi NG, Ye Z, Rickard AP, Khaw KT, Luben R, Langenberg C, Wareham NJ. Circulating 25-hydroxyvitamin D concentration and the risk of type 2 diabetes: results from the European Prospective Investigation into Cancer (EPIC)-Norfolk cohort and updated meta-analysis of prospective studies. Diabetologia 2012;55:2173–82.

9. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009;19:468–83.

10. Ginde AA, Mansbach JM, Camargo CA Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009;169:384–90.

11. Grandi NC, Breitling LP, Brenner H. Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med 2010;51:228–33.

12. Iribab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnvoeten FJ, Norat T, Pischon T, Jansen EH, Slimani N, Byrnes G, Rinaldi S, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 2010;340:b5500.

13. Pludowski P, Holick MF, Pilz S, Wagner CL, Grant WB, Sluiter J, Llewellyn DJ, Kienreich K, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality—a review of recent evidence. Autoimmun Rev 2013;12:976–89.

14. Schöttler B, Ball D, Gellert C, Brenner H. Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Res Rev 2013;12:708–18.

15. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014;348:g2035.

16. Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for treatment and prevention of infectious diseases: a systematic review of randomized controlled trials. Endocr Pract 2009;15:438–49.

17. Yin L, Mena JM, Chen T, Schottker B, Arndt V, Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: a systematic review and meta-analysis. Prev Med 2013;57:753–64.

18. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80 (suppl 1):95–103.

19. Khaw KT, Reeve J, Luben R, Bingham S, Welch A, Wareham N, Oakes S, Day N. Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet 2004;363:197–202.

20. Shohaimi S, Welch A, Bingham S, Luben R, Day N, Wareham N, Khaw KT. Area deprivation predicts lung function independently of education and social class. Eur Respir J 2004;24:157–61.

21. Wareham NJ, Rains RW, Rennie KL, Schuit AJ, Mitchell J, Hennings S, Day NE. Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutr 2003;6:407–13.

22. Mulligan AA, Luben RN, Bhaniani A, Parry-Smith DJ, O’Connor L, Khawaja AP, Forouhi NG, Khaw KT. A new tool for converting food frequency questionnaire data into nutrient and food group values: FETA research methods and availability. BMJ Open 2014;4:e004503.

23. Riemersma RA, Oliver M, Elton RA, Altham PG, Vartiainen E, Salo M, Rubba P, Mancini M, Georgi H, Vuilleumier JP. Plasma antioxidants and coronary heart disease: vitamins C and E, and selenium. Eur J Clin Nutr 1990:44:143–50.

24. Khaw KT, Bingham S, Welch A, Luben R, Wareham N, Oakes S, Day N. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. European Prospective Investigation into Cancer and Nutrition. Lancet 2001;357:65–63.

25. Mellhus H, Snellman G, Gedeogb R, Byberg L, Berglund L, Mallmin H, Hellman P, Blomhoff R, Hagstrom E, Arnlov J, et al. Plasma 25-hydroxyvitamin D levels and fracture risk in a community-based cohort of elderly men in Sweden. J Clin Endocrinol Metab 2010;95:2637–45.

26. Laurant GA, Barjon NA, Snellman G, Gedeogb R, Byberg L, Sundstrom J, Arnlov J, Hellman P, Blomhoff R, et al. Plasma vitamin D and mortality in older men: a community-based prospective cohort study. Am J Clin Nutr 2010;92:841–8.

27. Snellman G, Mellhus H, Gedeogb R, Byberg L, Berglund L, Wernoth L, Michaelsson K. Determining vitamin D status: a comparison between commercially available assays. PLoS ONE 2010.5:e11555.

28. Rizzoli R, Boonen S, Brandi ML, Bruyere O, Cooper C, Kanis JA, Kaufman JM, Ringe JD, Weryga G, Register JT. Vitamin D supplementation in elderly or postmenopausal women: a 2013 update of the 2008 recommendations from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Curr Med Res Opin 2013;29:305–13.

29. Auvert P, Gandini S. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167:730–73.

30. Avenell A, MacLennan GS, Jenkinson DJ, McPherson GC, McDonald AM, Pant PR, Grant AM, Campbell MK, Anderson FH, Cooper C, et al. Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D3 and/or calcium (RECORD trial). J Clin Endocrinol Metab 2012;97:614–22.

31. Bischoff-Ferrari HA. Vitamin D and fracture prevention. Rheum Dis Clin North Am 2012;38:107–13.

32. Brunner RL, Wactawski-Wende J, Caan BJ, Cochrane BB, Chlebowski RT, Gass ML, Jacobs ET, LaCroix AZ, Lane D, Larson J, et al. The effect of calcium plus vitamin D on risk of invasive cancer: results of the Women’s Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. Nutr Cancer 2011;63:387–41.

33. Prentice RL, Pettinger MB, Jackson RD, Wactawski-Wende J, LaCroix AZ, Anderson GL, Chlebowski RT, Manson JE, Van HL, Vitolins MZ, et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporsis Int 2013;24:567–80.

34. Romagnoli E, Mascia ML, Ciprijani C, Fassino V, Mazzesi F, D’Erasmo E, Carnevale V, Scillitani A, Minisola S. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 2008;93:3015–20.

35. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006;84:694–7.

36. Rush L, McCarthy G, Walsh D, Mackay D. Vitamin D and subsequent all-age and premature mortality: a systematic review. BMC Public Health 2013;13:679.
37. Lensmeyer G, Poquette M, Wiebe D, Binkley N. The C-3 epimer of 25-hydroxyvitamin D(3) is present in adult serum. J Clin Endocrinol Metab 2012;97:163–8.
38. Schöttker B, Jansen EH, Haug U, Schomburg L, Kohrle J, Brenner H. Standardization of misleading immunoassay based 25-hydroxyvitamin D levels with liquid chromatography tandem-mass spectrometry in a large cohort study. PLoS ONE 2012;7:e48774.
39. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ 2003;326:469.
40. Hansdottir S, Monick MM. Vitamin D effects on lung immunity and respiratory diseases. Vitam Horm 2011;86:217–37.
41. Leu M, Giovannucci E. Vitamin D: epidemiology of cardiovascular risks and events. Best Pract Res Clin Endocrinol Metab 2011;25:633–46.
42. Schöttker B, Haug U, Schomburg L, Kohrle J, Perna L, Muller H, Holleczek B, Brenner H. Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr 2013;97:782–93.
43. Welsh P, Doolin O, McConnachie A, Boulton E, McNeil G, Macdonald H, Hardcastle A, Hart C, Upton M, Watt G, et al. Circulating 25OHD, dietary vitamin D, PTH, and calcium associations with incident cardiovascular disease and mortality: the MIDSPAN Family Study. J Clin Endocrinol Metab 2012;97:4578–87.
44. Sachs MC, Shoben A, Levin GP, Robinson-Cohen C, Hoofnagle AN, Swords-Jenny N, Ix JH, Budoff M, Lutsey PL, Siscovick DS, et al. Estimating mean annual 25-hydroxyvitamin D concentrations from single measurements: the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr 2013;97:1243–51.